...
首页> 外文期刊>Journal of Molecular Liquids >Gold(III) complex from pyrimidine and morpholine analogue Schiff base ligand: Synthesis, characterization, DFT, TDDFT, catalytic, anticancer, molecular modeling with DNA and BSA and DNA binding studies
【24h】

Gold(III) complex from pyrimidine and morpholine analogue Schiff base ligand: Synthesis, characterization, DFT, TDDFT, catalytic, anticancer, molecular modeling with DNA and BSA and DNA binding studies

机译:来自嘧啶和吗啉代类似物席夫碱配体的金(III)复合物:合成,表征,DFT,TDDFT,催化,抗癌,分子建模与DNA和BSA和DNA结合研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

New gold(III) complex, [AuL2]Cl-3 was synthesized from (2-(4-morpholinobenzylidene)-1-(4-(trifluoromethyl) pyrimidin-2-yl)hydrazine) and characterized by analytical and miscellaneous spectral methods. These results show that Au(III) complex has square planar geometry. Density functional theory (DFT) calculations have been done to understand the electronic structure of the Au(III) complexand free ligand while time dependent density functional theory (TDDFT) calculations have been employed to compute absorption spectra of ligand and Au(III) complex. Antimicrobial results suggest that ligand and complex have been inhibited the E. coli bacteria (13 mm) and C albicans fungi (16 mm) than other microbes. Antioxidant results exhibit the ligand and complex has enhanced scavenging activities against several free radicals. In vitro anticancer activities of cisplatin, ligand and complex have been explored by MIT assay against various human cancer cell lines (breast-MCF-7, liver-HepG2, cervical-HeLa, lung-A549) and one normal cell line (NHDF- normal human dermal fibroblasts). The results show that complex has low IC50 values against cancer cell lines (20.6 +/- 0.98 mu g/mL, MCF-7; 22.68 +/- 1.13 mu g/mL, HepG2; 32.00 +/- 1.60 mu g/mL, HeLa; 33.19 +/- 1.66 mu g/mL, A549) than ligand. Moreover, complex has ten times least toxic activity (109.65 +/- 5.48 mu g/mL) on NHDF cell line as compared to cisplatin (10.28 +/- 0.51 mu g/mL). Based on the least toxic activity of complex has been further discovered by in vivo anticancer study using Ehrlich Ascites Carcinoma (EAC) tumor bearing Swiss albino mice. DNA interactions of ligand and complex have been studied by electronic absorption, fluorescence, viscometric and cyclic voltammetic methods. The results suggest that ligand and complex binds with CT-DNA through an intercalative interaction. Further confirm the nature of interaction between ligand and Au(III) complex towards DNA and BSA protein, molecular docking analysis has been carried out. These results reveal that Au(III) complex shows greater binding ability towards DNA and BSA than the ligand. (C) 2019 Elsevier B.V. All rights reserved.
机译:新的金(III)复合物,[AUL2] C1-3由(2-(4-(4-)(4-(4-)(4-大甲苯基苄基)-1-(4-(三氟甲基)嘧啶-2-基)肼合成,并通过分析和杂项光谱方法表征。这些结果表明,AU(III)复合物具有方形平面几何形状。已经完成了密度函数理论(DFT)计算以了解Au(iii)络合物和自由配体的电子结构,同时采用时间依赖性密度函数理论(TDDFT)计算来计算配体和Au(III)复合物的吸收光谱。抗微生物的结果表明配体和复合物已被抑制大肠杆菌(13mm)和C醛糖苷真菌(16毫米)比其他微生物。抗氧化结果表现出配体和复合物具有增强的扫除活性,针对几种自由基。通过麻省理工学院测定对各种人类癌细胞系(乳腺MC-7,肝脏-HEPG2,宫颈 - HELA,肺-A549)和一种正常细胞系(NHDF-正常)来探讨SITPLATIN,配体和复合物的体外抗癌活性。人类皮肤成纤维细胞)。结果表明,复杂的癌细胞系具有低IC 50值(20.6 +/-0.98μg/ ml,MCF-7; 22.68 +/-1.13μg/ ml,Hepg2; 32.00 +/- 1.60 mu g / ml, Hela; 33.19 +/- 1.66 mu g / ml,a549)比配体。此外,与顺铂(10.28 +/-0.51μmg/ ml)相比,复合物在NHDF细胞系上具有10倍最小的毒性活性(109.65 +/-5.48μmg/ ml)。基于综合复合物的最低毒性,通过使用EHRLICH腹水癌(EAC)肿瘤携带瑞士白化小鼠的体内抗癌研究进一步发现。通过电子吸收,荧光,粘度和循环伏粘液方法研究了配体和复合物的DNA相互作用。结果表明,配体和复合物通过间隔相互作用与CT-DNA结合。进一步证实配体与Au(III)复合物之间的相互作用的性质朝向DNA和BSA蛋白,进行了分子对接分析。这些结果表明,AU(III)复合物显示比配体的DNA和BSA更大的结合能力。 (c)2019 Elsevier B.v.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号